GoKawiilThe use of genetically modified immune cells called chimeric antigen receptor (CAR) T cells is a standard therapy for certain relapsed or treatment-resistant cancers1, including leukaemia, lymphoma and myeloma. The approach, a type of immunotherapy, is also under evaluation for some difficult-to-treat autoimmune diseases2. Writing in Nature, Nyberg et al.3 present a gene-editing strategy that can create CAR T cells directly in the bodies of mice (in vivo), circumventing the production hurdles that currently limit their clinical use.
doi: https://doi.org/10.1038/d41586-026-00634-5
References Cappell, K. M. & Kochenderfer, J. N. Nature Rev. Clin. Oncol. 20, 359–371 (2023). Müller, F. et al. N. Engl. J. Med. 390, 687–700 (2024). Nyberg, W. A. et al. Nature https://doi.org/10.1038/s41586-026-10235-x (2026). Bot, A. et al. Nature Rev. Drug Discov. 25, 116–137 (2026). Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Trends Pharmacol. Sci. 45, 406–418 (2024). Ruella, M. et al. Nature Med. 24, 1499–1503 (2018). Eyquem, J. et al. Nature 543, 113–117 (2017). Tix, T. et al. Clin Cancer Res. 30, 4690–4700 (2024). Hamilton, J. R. et al. Nature Biotechnol. 42, 1684–1692 (2024). Lickefett, B. et al. Front. Immunol. 14, 1303935 (2023). Download references
Competing Interests L.E. reports consulting activities and has received in-kind reagents from NanoVation Therapeutics. L.E. reports intellectual-property applications describing in vivo CAR-T-cell therapies.
Related Articles
Subjects